SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials
26 9월 2023 - 3:43PM
Business Wire
Promising outcomes indicate significant reductions in emergency
visits and hospital readmissions, alongside reductions in
healthcare utilization costs relating to post-MI patient
treatment
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL”
or the “Company”), a leading provider and developer of
advanced personal telemedicine solutions, is pleased to announce
the initial results from the Mayo Clinic HELP-MI and the Imperial
College London TELE-ACS trials, presented at the Vulnerable Plaque
and Patient Meeting (VPM) 2023 (as previously announced).
The initial findings from both trials, which focus on the
application of SHL's patented and FDA cleared SmartHeart® 12-lead
ECG technology for monitoring of post-MI (heart attack) patients at
home, have been nothing short of remarkable.
Key highlights from the presentation of the initial results
include:
- A staggering decrease of- 27.5% in emergency room visits in the
TELE-ACS trial1.
- Moreover, hospital readmission rates plummeted by -55% in the
TELE-ACS trial1.
- In the HELP-ME trial, cardiovascular-driven emergency
department visits for patients using the SmartHeart® device were
reduced to an astonishing 0 (zero)2.
- Cardiovascular driven rehospitalization was also at 0 (zero)2
for patients using the device in the HELP-ME trial.
- The presentation at the conference noted that the HELP-ME trial
demonstrated the potential of SHL's system be successfully
replicated in the US medical system, emphasizing its capability to
reduce non-indicated cardiovascular emergency department visits and
hospitalizations while improving early recognition of serious
cardiovascular presentations.
Erez Nachtomy, CEO of SHL Telemedicine, commented, "The initial
results from the HELP-MI and TELE-ACS trials have surpassed our
expectations. We are extremely confident in the potential of our
SmartHeart® technology, and these findings further validate its
efficacy in post-MI patient care. We are looking forward to the
continued positive impact our technology will have on telemedicine
and remote patient care."
Presentations of the trials from the VPM 2023 conference are
available at: https://www.millbrook-events.co.uk/VPM2023
About SHL Telemedicine SHL Telemedicine is engaged in
developing and marketing personal telemedicine systems and the
provision of medical call center services, with a focus on
cardiovascular and related diseases, to end users and to the
healthcare community. SHL Telemedicine offers its services and
personal telemedicine devices to subscribers utilizing telephonic
and Internet communication technology. SHL is listed on the SIX
Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957)
and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP:
78423T200). For more information, please visit our website at
www.shl-telemedicine.com.
Forward-Looking Statements Some of the information
contained in this press release contains forward-looking
statements. Readers are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ
materially from those in the forward-looking statements as a result
of various factors. SHL Telemedicine undertakes no obligation to
publicly update or revise any forward-looking statements.
1 Telemedicine group vs. control standard care group at 3 months
follow-up 2 Telemedicine group compliant users vs. control
group
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925392069/en/
For further information please contact: Fabienne Farner,
IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch
SHL Telemedicine (NASDAQ:SHLT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
SHL Telemedicine (NASDAQ:SHLT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024